Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer

Abstract

Purpose To determine the correlation between the volume of bone metastasis as assessed with diffusion-weighted (DW) imaging and established prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) and the association with overall survival (OS). Materials and Methods This retrospective study was approved by the institutional review board; informed consent was obtained from all patients. The authors analyzed whole-body DW images obtained between June 2010 and February 2013 in 53 patients with mCRPC at the time of starting a new line of anticancer therapy. Bone metastases were identified and delineated on whole-body DW images in 43 eligible patients. Total tumor diffusion volume (tDV) was correlated with the bone scan index (BSI) and other prognostic factors by using the Pearson correlation coefficient (r). Survival analysis was performed with Kaplan-Meier analysis and Cox regression. Results The median tDV was 503.1 mL (range, 5.6-2242 mL), and the median OS was 12.9 months (95% confidence interval [CI]: 8.7, 16.1 months). There was a significant correlation between tDV and established prognostic factors, including hemoglobin level (r = -0.521, P < .001), prostate-specific antigen level (r = 0.556, P < .001), lactate dehydrogenase level (r = 0.534, P < .001), alkaline phosphatase level (r = 0.572, P < .001), circulating tumor cell count (r = 0.613, P = .004), and BSI (r = 0.565, P = .001). A higher tDV also showed a significant association with poorer OS (hazard ratio, 1.74; 95% CI: 1.02, 2.96; P = .035). Conclusion Metastatic bone disease from mCRPC can be evaluated and quantified with whole-body DW imaging. Whole-body DW imaging-generated tDV showed correlation with established prognostic biomarkers and is associated with OS in mCRPC. (©) RSNA, 2016 Online supplemental material is available for this article.

Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI

“…Several reports have examined the prognostic value of tDV for metastatic bone tumors. In 2016, metastatic bone tumor from castration-resistant prostate cancer was evaluated with tDV generated by WB-DWI [33]. The tDV showed correlations with established prognostic biomarkers, including prostate-specific antigen level and bone scan index, and was associated with overall survival for the disease.…”

A risk‐based approach to identifying oligometastatic disease on imaging

“…Inter‐observer agreement for reading of WB‐MRI images including DWI has been evaluated as very good ( K = 0.87 [Confidence Interval 0.66; 1.00]) in several studies outperforming a moderate inter‐observer agreement for bone scintigraphy ( K = 0.60 [Confidence Interval 0.26; 0.78]) ADC maps provide information on the cellularity, viability and changes over time and are essential for lesion follow‐up under treatment. Finally, applying an ADC threshold to the images enables automated measurements of the global volume of metastatic disease, which can be exploited as prognostic and response biomarkers …”

“…Finally, applying an ADC threshold to the images enables automated measurements of the global volume of metastatic disease, which can be exploited as prognostic and response biomarkers. [65][66][67]…”

Quantifying bone structure, micro-architecture, and pathophysiology with MRI

“…This has been used to quantify burden of disease, which correlates with established prognostic biomarkers. 59 Furthermore ADC changes in individual lesions and globally in the whole body can be used to determine treatment response in patients with metastatic bone disease and myeloma. 60,18 Whole-body MRI has become the reference standard for assessment of multiple myeloma as it is more sensitive for marrow infiltration by plasma cells compared to conventional radiography and CT (Fig 2).…”